Axinn Successfully Argues for Claim Construction in Mayne v. Merck
December 27, 2016
A team of Axinn attorneys successfully argued on behalf of Mayne Pharma International Pty Ltd. in a claim construction hearing in the patent infringement action, Mayne Pharma International Pty Ltd. v. Merck & Co., Inc. and Merck Sharp & Dohme Corp. On December 27, 2016, Judge Leonard P. Stark of the United States District Court for the District of Delaware issued a favorable opinion and order construing the claims to be limited to humans, as well as rejecting Merck’s contentions that the claims are invalid for indefiniteness.
The patent infringement matter alleges that Merck’s Noxafil® tablets infringe Mayne's U.S. Patent No. 6,881,745, which relates to pharmaceutical compositions for poorly soluble, antifungal drugs.
The team of Axinn attorneys consisted of Jason Murata, Thomas Hedemann, and Matt Murphy.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
DC Bar: The DOJ's New Antitrust Whistleblower Rewards Program: An Overview and the Road Ahead
Speaking Engagement
Antitrust
Informa Antitrust Midwest 2026
Speaking Engagement
Antitrust
National LGBTQ+ Bar Association Lavender Law Conference and Career Fair 2026
Sponsorship
What’s Up? Enforcement Updates From the Middle East and Africa
Podcast
Antitrust
AHLA Annual Meeting & In-House Counsel Program
Sponsorship
Antitrust
Lexology In-Depth: Intellectual Property and Antitrust (2026)
Byline Articles
Intellectual Property
Tracking The Rare 'Quick Look' Win In FTC's Zillow-Redfin Suit
Byline Articles
Antitrust
Gleiss Lutz Annual Antitrust Law Conference
Speaking Engagement
Antitrust
What Top Law Firms Say New Lawyers Need in the AI Era
Media Mentions
What’s the Role of Communications Strategy in M&A? How Public Affairs Impacts Antitrust
Podcast
Antitrust